NQO1 and prostate adenocarcinoma: In addition, the upregulation of NQO1 and downregulation of NRF2 in bladder urothelial carcinoma, lung adenocarcinoma, ovarian serous cystadenocarcinoma, prostate adenocarcinoma, skin cutaneous melanoma, testicular germ cell tumors, uterine corpus endometrial carcinoma, and uterine carcinosarcoma, indicatesthe inconsistent direction of changes observed between the NQO1 and NRF2 expression level may be related to differences in the methylation levels (Supplementary Figure S2B).